Pulse Biosciences Inc - PLSE STOCK NEWS

Pulse Biosciences (Nasdaq: PLSE) has received Health Canada approval for its CellFX® System, enabling its use in dermatological procedures targeting benign lesions, such as sebaceous hyperplasia and warts. This regulatory approval marks a significant milestone, following previous clearances from the FDA and CE mark earlier this year. The company plans to expand its controlled launch of CellFX across select Canadian medical practices and aims to recruit approximately 80 participating practices in North America and Europe. The CellFX System utilizes Nano-Pulse Stimulation™ technology to non-thermally clear targeted cells.

Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its participation in the Jefferies Virtual Healthcare Conference, scheduled for June 2, 2021, at 12:30pm PT. The company is known for its innovative CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, designed to treat various dermatologic conditions effectively. The CellFX System represents a significant advancement in bioelectric medicine, offering a non-thermal method that targets specific cells while preserving surrounding tissues. Interested viewers can access the webcast through the company’s website.

Pulse Biosciences (Nasdaq: PLSE) announced the presentation of four clinical studies on its Nano-Pulse Stimulation (NPS) technology at the ASLMS Virtual Annual Meeting on May 15-16, 2021. The studies focus on treating benign skin lesions, including back acne, common nevi, sebaceous hyperplasia, and cutaneous warts. The NPS technology demonstrated promising efficacy, with significant lesion clearance rates and minimal skin effects. Results suggest NPS could meet unmet medical needs in dermatology. The company's commitment to innovation in bioelectric medicine is highlighted by these advancements.

Pulse Biosciences (PLSE) reported its Q1 2021 financial results, highlighting significant progress in the rollout of its CellFX System Controlled Launch program, onboarding 15 aesthetic practices. The company submitted a final response to Health Canada for the CellFX System Medical Device License, with completion expected by Q2. FDA IDE approval was received for a feasibility study on basal cell carcinoma treatment. Financially, cash and investments reached $59.9 million, though GAAP net loss increased to $18.6 million from $11.9 million YoY, reflecting rising operational expenses.

Pulse Biosciences, Inc. (Nasdaq: PLSE) is set to report its first-quarter 2021 financial results on May 10, 2021, post-market close. A conference call will follow at 1:30 PM PT, where management will discuss the financial outcomes. Interested investors can join by dialing the provided numbers or by accessing the webcast available on the company's investor relations website. Pulse Biosciences is dedicated to advancing its Nano-Pulse Stimulation™ (NPS™) technology, notably through its CellFX® System, which targets dermatologic conditions while ensuring non-thermal clearance of cells.

Pulse Biosciences (Nasdaq: PLSE) presented an ePoster at the American Academy of Dermatology's Virtual Annual Meeting on April 23-25, 2021. The research, conducted by Collective Acumen, surveyed 405 aesthetic patients regarding their motivations for clearing benign skin lesions. Results revealed that 76% of respondents valued the new CellFX procedure more highly than popular aesthetic treatments like botulinum toxin or fillers. CEO Darrin Uecker emphasized the demand for effective, aesthetically appealing solutions. The company also launched CellFX.com for additional resources.

Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its participation in two upcoming virtual investor conferences. On March 10, 2021, management will engage in one-on-one meetings at the H.C. Wainwright Global Life Sciences Conference, with a presentation webcast available on March 9, 2021. Additionally, on March 17, 2021, the company will participate in an aesthetic dermatology panel discussion at the Maxim Emerging Growth Virtual Conference, featuring a live webcast at 2:00pm ET. Interested parties can access on-demand webcasts via the company’s website.

Pulse Biosciences (Nasdaq: PLSE) reported its fourth quarter and full-year financial results for 2020. The company secured FDA clearance and CE mark approval for its CellFX® System, enhancing its market position in aesthetic dermatology. As of December 31, 2020, cash and investments totaled $20.5 million, a decrease from $29.6 million in Q3 2020. Despite a net loss of $13.8 million for Q4 2020, the company maintained operational focus, with minimal pandemic impact on its processes. The launch of its Controlled Launch program for the CellFX System is expected to drive long-term growth.

Pulse Biosciences (Nasdaq: PLSE) has successfully completed the first CellFX procedures in the European Union, marking a critical milestone in its controlled launch program. The CellFX System, which utilizes Nano-Pulse Stimulation™ technology, is designed to non-thermally treat common benign lesions, enhancing patient satisfaction. A survey highlighted that patients prioritize treatment for skin lesions, with an average of 200 cases per month per aesthetic dermatologist. The company aims to establish best practices with leading specialists across Europe, while concurrently launching in the U.S.